In September ----, German healthcare company Fresenius agreed a EUR-.-bn (USD-.-bn) leveraged buy-out for Spain s largest private hospital operator Quironsalud, expecting the transaction to be completed by early ----. ...leveraged buy-out for Spain s largest private hospital operator Quironsalud, expecting the transaction to be completed by early ----. In August ----, Orexigen Therapeutics Ireland and Laboratorios Farmaceuticos Rovi executed a commercialisation and distributorship agreement for Mysimba (naltrexone HCl /bupropion HCl prolonged release) in Spain. In July ----, Funds advised by Apax Partners entered into a definitive agreement to acquire the operating subsidiaries of Invent Farma, a Spanish pharmaceutical company, from a consortium of investors led by ...In August ----, Orexigen Therapeutics Ireland and Laboratorios Farmaceuticos Rovi executed a commercialisation and distributorship agreement for Mysimba (naltrexone HCl /bupropion HCl prolonged release) in Spain. In July ----, Funds advised by Apax Partners entered into a definitive agreement to acquire the operating subsidiaries of Invent Farma, a Spanish pharmaceutical company, from a consortium of investors led by
...In our Pharmaceutical Risk/Reward Index for Q---, Spain scored --.- and ranked --th out of the -- countries surveyed in Western Europe - just below the Netherlands (--.-). While Spain offers investors positive features, such as its large drug market (Market Expenditure score of --.- out of --) and a high pensionable population (score of -.- out of -), it also has problems, such as the government s focus on cost containment, low population growth (score of -.- out of -), cumbersome bureaucracy and provincial differences regarding drug regulations and reimbursement. ...
...BMI View: Growth in the Spanish pharmaceutical market will remain sluggish in the coming years. Despite returning to growth in ----, the market is unlikely to recover to its ---- peak value until ----. ...Despite returning to growth in ----, the market is unlikely to recover to its ---- peak value until ----. An aging population and a high chronic disease burden will drive demand for patented medicines, which account for the vast majority of the total market. Implementation of further drug price caps across the pharmaceutical sector as the government looks to contain spiralling healthcare cost, pose downside risks to our forecast. ...An aging population and a high chronic disease burden will drive demand for patented medicines, which account for the vast majority of the total market. Implementation of further drug price caps across the pharmaceutical sector as the government looks to contain spiralling healthcare cost, pose downside risks to our forecast.
...
